[
    {
        "id": 6195,
        "drug_name": "VAXNEUVANCE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pneumococcal disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-16",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210716005480\/en\/",
        "note": "FDA approval announced July 16, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5060,
        "drug_name": "BYLVAY (odevixibat)",
        "clinical_trial_id": "NCT03566238",
        "has_trial_insight_page": 0,
        "indication": "Progressive familial intrahepatic cholestasis (PFIC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-20",
        "link": "https:\/\/ir.albireopharma.com\/news-releases\/news-release-details\/albireo-announces-fda-approval-bylvaytm-odevixibat-first-drug",
        "note": "FDA approval announced July 20, 2021.",
        "company_entity_id": 2251,
        "company_ticker": "IPSEY",
        "company_name": "Ipsen ADR",
        "company_price": "29.1600",
        "company_change": 0.03,
        "company_percent_change": 0.1,
        "company_optionable": 0,
        "company_number_of_shares": 328117684,
        "price_change_sparkline": [
            [
                29.095,
                1706677200
            ],
            [
                28.85,
                1706763600
            ],
            [
                28.85,
                1706850000
            ],
            [
                28,
                1707109200
            ],
            [
                28.28,
                1707195600
            ],
            [
                29.2,
                1707282000
            ],
            [
                28.495,
                1707368400
            ],
            [
                28.664,
                1707454800
            ],
            [
                28.664,
                1707714000
            ],
            [
                28.22,
                1707800400
            ],
            [
                27.82,
                1707886800
            ],
            [
                28.5,
                1707973200
            ],
            [
                28.405,
                1708059600
            ],
            [
                28.874,
                1708405200
            ],
            [
                28.0425,
                1708491600
            ],
            [
                28.295,
                1708578000
            ],
            [
                28.4675,
                1708664400
            ],
            [
                28.06,
                1708923600
            ],
            [
                28.185,
                1709010000
            ],
            [
                27.67,
                1709096400
            ],
            [
                27.86,
                1709182800
            ],
            [
                27.74,
                1709269200
            ],
            [
                27.78,
                1709528400
            ],
            [
                27.498,
                1709614800
            ],
            [
                27.69,
                1709701200
            ],
            [
                28.69,
                1709787600
            ],
            [
                28.31,
                1709874000
            ],
            [
                29.13,
                1710129600
            ],
            [
                29.16,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2682,
        "drug_name": "BYDUREON BCise",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Type 2 diabetes (Pediatric)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210723005083\/en\/",
        "note": "FDA approval announced July 23, 2021.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7995,
        "drug_name": "DALVANCE (dalbavancin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute bacterial skin and skin structure infections (ABSSSI) - pediatric",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-23",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-pediatric-patients-301340347.html",
        "note": "FDA approval announced July 23, 2021.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4987,
        "drug_name": "KEYTRUDA (pembrolizumab) - (KEYNOTE-522)",
        "clinical_trial_id": "NCT03036488",
        "has_trial_insight_page": 0,
        "indication": "Triple negative breast cancer (TNBC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210727005394\/en\/",
        "note": "FDA approval announced July 27, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4617,
        "drug_name": "Twyneo",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acne",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-27",
        "link": "https:\/\/ir.sol-gel.com\/news-releases\/news-release-details\/sol-gel-technologies-announces-fda-approval-twyneor",
        "note": "FDA approval announced July 27, 2021.",
        "company_entity_id": 528,
        "company_ticker": "SLGL",
        "company_name": "Sol-Gel Technologies Ltd.",
        "company_price": "1.0550",
        "company_change": -0.040000000000000036,
        "company_percent_change": -3.57,
        "company_optionable": 1,
        "company_number_of_shares": 25702240,
        "price_change_sparkline": [
            [
                1.4,
                1706677200
            ],
            [
                1.5,
                1706763600
            ],
            [
                1.39,
                1706850000
            ],
            [
                1.25,
                1707109200
            ],
            [
                1.3,
                1707195600
            ],
            [
                1.25,
                1707282000
            ],
            [
                1.2475,
                1707368400
            ],
            [
                1.3,
                1707454800
            ],
            [
                1.3,
                1707714000
            ],
            [
                1.2699,
                1707800400
            ],
            [
                1.08,
                1707886800
            ],
            [
                1.115,
                1707973200
            ],
            [
                1.17,
                1708059600
            ],
            [
                1.19,
                1708405200
            ],
            [
                1.11,
                1708491600
            ],
            [
                1.1199,
                1708578000
            ],
            [
                1.106,
                1708664400
            ],
            [
                1.0869,
                1708923600
            ],
            [
                0.9521,
                1709010000
            ],
            [
                1.18,
                1709096400
            ],
            [
                1.12,
                1709182800
            ],
            [
                1.1325,
                1709269200
            ],
            [
                1.05,
                1709528400
            ],
            [
                1.07,
                1709614800
            ],
            [
                1.0527,
                1709701200
            ],
            [
                1.1,
                1709787600
            ],
            [
                1.1,
                1709874000
            ],
            [
                1.094,
                1710129600
            ],
            [
                1.055,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8034,
        "drug_name": "BOTOX",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Upper Limb Spasticity",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-29",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity-301343906.html",
        "note": "FDA approval announced July 29, 2021.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5036,
        "drug_name": "NUCALA (Mepolizumab)",
        "clinical_trial_id": "NCT03085797",
        "has_trial_insight_page": 0,
        "indication": "Chronic rhinosinusitis with nasal polyps",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-29",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210729006206\/en\/",
        "note": "FDA approval announced July 29, 2021.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10142,
        "drug_name": "UPTRAVI (selexipag)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pediatric pulmonary arterial hypertension (PAH)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-31",
        "link": "https:\/\/www.jnj.com\/uptravi-selexipag-receives-fda-approval-for-intravenous-use-in-adult-patients-with-pulmonary-arterial-hypertension-pah",
        "note": "Approved July 30, 2021.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2785,
        "drug_name": "Nexviazyme (avalglucosidase alfa)",
        "clinical_trial_id": "NCT02782741",
        "has_trial_insight_page": 0,
        "indication": "Pompe disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-06",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-pompe-disease?utm_medium=email&utm_source=govdelivery",
        "note": "FDA approval announced August 6, 2021.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7176,
        "drug_name": "KEYTRUDA (pembrolizumab)and LENVIMA (lenvatinib)",
        "clinical_trial_id": "NCT02811861",
        "has_trial_insight_page": 0,
        "indication": "Renal Cell Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-11",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210811005902\/en\/",
        "note": "FDA approval announced August 11, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5289,
        "drug_name": "XYWAV",
        "clinical_trial_id": "NCT03533114",
        "has_trial_insight_page": 0,
        "indication": "Idiopathic Hypersomnia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-12",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-announces-us-fda-approval-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-in-adults-301354616.html",
        "note": "FDA approval announced August 12, 2021.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 7595,
        "drug_name": "WELIREG (Belzutifan)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Von Hippel-Lindau Syndrome",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-13",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210813005437\/en\/",
        "note": "FDA approval announced August 13, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7520,
        "drug_name": "TicoVac",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Tick-borne encephalitis (TBE) vaccine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-13",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210813005441\/en\/",
        "note": "FDA Approval announced August 13, 2021",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8153,
        "drug_name": "JEMPERLI (Dostarlimab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Mismatch repair deficient (dMMR) solid tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-17",
        "link": "https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/fda-grants-accelerated-approval-jemperli-dostarlimab-gxly-dmmr",
        "note": "FDA Approval announced August 27, 2021.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8153,
        "drug_name": "JEMPERLI (Dostarlimab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Mismatch repair deficient (dMMR) solid tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-17",
        "link": "https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/fda-grants-accelerated-approval-jemperli-dostarlimab-gxly-dmmr",
        "note": "FDA Approval announced August 27, 2021.",
        "company_entity_id": 394,
        "company_ticker": "ANAB",
        "company_name": "AnaptysBio Inc.",
        "company_price": "26.0600",
        "company_change": 2.71,
        "company_percent_change": 11.61,
        "company_optionable": 1,
        "company_number_of_shares": 26575178,
        "price_change_sparkline": [
            [
                23.6,
                1706677200
            ],
            [
                24.25,
                1706763600
            ],
            [
                24.01,
                1706850000
            ],
            [
                24.07,
                1707109200
            ],
            [
                24.02,
                1707195600
            ],
            [
                23.51,
                1707282000
            ],
            [
                23.13,
                1707368400
            ],
            [
                23.01,
                1707454800
            ],
            [
                23.07,
                1707714000
            ],
            [
                22.01,
                1707800400
            ],
            [
                22.29,
                1707886800
            ],
            [
                22.76,
                1707973200
            ],
            [
                24.1,
                1708059600
            ],
            [
                23.83,
                1708405200
            ],
            [
                25.49,
                1708491600
            ],
            [
                25.28,
                1708578000
            ],
            [
                25.87,
                1708664400
            ],
            [
                26.46,
                1708923600
            ],
            [
                26.47,
                1709010000
            ],
            [
                25.81,
                1709096400
            ],
            [
                25.53,
                1709182800
            ],
            [
                25.45,
                1709269200
            ],
            [
                26.15,
                1709528400
            ],
            [
                25.33,
                1709614800
            ],
            [
                25.49,
                1709701200
            ],
            [
                24.63,
                1709787600
            ],
            [
                24.8,
                1709874000
            ],
            [
                23.35,
                1710129600
            ],
            [
                26.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6881,
        "drug_name": "JARDIANCE (empagliflozin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Heart failure with reduced ejection fraction",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-18",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-jardiance-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction-301358260.html",
        "note": "FDA approval announced August 18, 2021.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5431,
        "drug_name": "OPDIVO (nivolumab)",
        "clinical_trial_id": "NCT02632409",
        "has_trial_insight_page": 0,
        "indication": "Urothelial Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-20",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210820005285\/en\/",
        "note": "FDA approval announced August 20, 2021.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8165,
        "drug_name": "Gvoke Kit",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hypoglycemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210823005077\/en\/",
        "note": "FDA approval August 23, 2021. ",
        "company_entity_id": 562,
        "company_ticker": "XERS",
        "company_name": "Xeris Biopharma Holdings Inc.",
        "company_price": "2.2100",
        "company_change": -0.040000000000000036,
        "company_percent_change": -1.78,
        "company_optionable": 1,
        "company_number_of_shares": 140453467,
        "price_change_sparkline": [
            [
                2.46,
                1706677200
            ],
            [
                2.51,
                1706763600
            ],
            [
                2.45,
                1706850000
            ],
            [
                2.47,
                1707109200
            ],
            [
                2.64,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.73,
                1707368400
            ],
            [
                2.87,
                1707454800
            ],
            [
                2.95,
                1707714000
            ],
            [
                2.87,
                1707800400
            ],
            [
                3.21,
                1707886800
            ],
            [
                3.21,
                1707973200
            ],
            [
                3.22,
                1708059600
            ],
            [
                3.16,
                1708405200
            ],
            [
                3,
                1708491600
            ],
            [
                3.04,
                1708578000
            ],
            [
                3.01,
                1708664400
            ],
            [
                3.11,
                1708923600
            ],
            [
                3.13,
                1709010000
            ],
            [
                3.02,
                1709096400
            ],
            [
                3.075,
                1709182800
            ],
            [
                3.18,
                1709269200
            ],
            [
                3.04,
                1709528400
            ],
            [
                3.08,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.44,
                1709787600
            ],
            [
                2.35,
                1709874000
            ],
            [
                2.25,
                1710129600
            ],
            [
                2.21,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4590,
        "drug_name": "KORSUVA (CR845\/difelikefalin) injection",
        "clinical_trial_id": "NCT03636269",
        "has_trial_insight_page": 0,
        "indication": "Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-23",
        "link": "https:\/\/ir.caratherapeutics.com\/news-releases\/news-release-details\/cara-therapeutics-and-vifor-pharma-announce-us-fda-approval",
        "note": "FDA approval announced August 23, 2021.",
        "company_entity_id": 77,
        "company_ticker": "CARA",
        "company_name": "Cara Therapeutics Inc.",
        "company_price": "0.8800",
        "company_change": -0.06999999999999995,
        "company_percent_change": -7.36,
        "company_optionable": 1,
        "company_number_of_shares": 54656413,
        "price_change_sparkline": [
            [
                0.5656,
                1706677200
            ],
            [
                0.5609,
                1706763600
            ],
            [
                0.5741,
                1706850000
            ],
            [
                0.5812,
                1707109200
            ],
            [
                0.5769,
                1707195600
            ],
            [
                0.5323,
                1707282000
            ],
            [
                0.5201,
                1707368400
            ],
            [
                0.5658,
                1707454800
            ],
            [
                0.583,
                1707714000
            ],
            [
                0.5332,
                1707800400
            ],
            [
                0.5651,
                1707886800
            ],
            [
                0.5953,
                1707973200
            ],
            [
                0.6262,
                1708059600
            ],
            [
                0.6423,
                1708405200
            ],
            [
                0.6762,
                1708491600
            ],
            [
                0.7988,
                1708578000
            ],
            [
                0.9071,
                1708664400
            ],
            [
                0.8011,
                1708923600
            ],
            [
                0.9455,
                1709010000
            ],
            [
                0.89,
                1709096400
            ],
            [
                0.8502,
                1709182800
            ],
            [
                0.95,
                1709269200
            ],
            [
                0.9998,
                1709528400
            ],
            [
                0.91,
                1709614800
            ],
            [
                0.9901,
                1709701200
            ],
            [
                1.05,
                1709787600
            ],
            [
                0.9814,
                1709874000
            ],
            [
                0.95,
                1710129600
            ],
            [
                0.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3372,
        "drug_name": "SKYTROFA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Growth hormone deficiency in children",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-25",
        "link": "https:\/\/investors.ascendispharma.com\/news-releases\/news-release-details\/ascendis-pharma-announces-us-food-and-drug-administration",
        "note": "FDA approval announced August 25, 2021.",
        "company_entity_id": 49,
        "company_ticker": "ASND",
        "company_name": "Ascendis Pharma A\/S",
        "company_price": "153.8000",
        "company_change": 5.63,
        "company_percent_change": 3.8,
        "company_optionable": 1,
        "company_number_of_shares": 56614385,
        "price_change_sparkline": [
            [
                129.93,
                1706677200
            ],
            [
                141.63,
                1706763600
            ],
            [
                139.77,
                1706850000
            ],
            [
                143.09,
                1707109200
            ],
            [
                140.84,
                1707195600
            ],
            [
                139.29,
                1707282000
            ],
            [
                139.25,
                1707368400
            ],
            [
                141.75,
                1707454800
            ],
            [
                144.59,
                1707714000
            ],
            [
                143.35,
                1707800400
            ],
            [
                146.61,
                1707886800
            ],
            [
                147.2,
                1707973200
            ],
            [
                156.39,
                1708059600
            ],
            [
                156.76,
                1708405200
            ],
            [
                157.14,
                1708491600
            ],
            [
                158.2,
                1708578000
            ],
            [
                159.4,
                1708664400
            ],
            [
                157.54,
                1708923600
            ],
            [
                155.34,
                1709010000
            ],
            [
                146.93,
                1709096400
            ],
            [
                147.76,
                1709182800
            ],
            [
                152.47,
                1709269200
            ],
            [
                147.99,
                1709528400
            ],
            [
                150.55,
                1709614800
            ],
            [
                146.02,
                1709701200
            ],
            [
                146.28,
                1709787600
            ],
            [
                146.62,
                1709874000
            ],
            [
                148.17,
                1710129600
            ],
            [
                153.8,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5179,
        "drug_name": "KEYTRUDA (pembrolizumab) - KN-361",
        "clinical_trial_id": "NCT02853305",
        "has_trial_insight_page": 0,
        "indication": "Bladder cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-08-31",
        "link": "https:\/\/www.merck.com\/news\/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer\/",
        "note": "FDA approval announced August 31, 2021. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3400,
        "drug_name": "BRUKINSA (zanubrutinib)",
        "clinical_trial_id": "NCT03053440",
        "has_trial_insight_page": 0,
        "indication": "Waldenstr\u00f6m\u2019s macroglobulinemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210901006049\/en\/",
        "note": "FDA Approval announced September 1, 2021.",
        "company_entity_id": 340,
        "company_ticker": "BGNE",
        "company_name": "BeiGene Ltd.",
        "company_price": "163.7500",
        "company_change": -0.78,
        "company_percent_change": -0.47,
        "company_optionable": 1,
        "company_number_of_shares": 104577940,
        "price_change_sparkline": [
            [
                148.23,
                1706677200
            ],
            [
                149.93,
                1706763600
            ],
            [
                144.48,
                1706850000
            ],
            [
                141.81,
                1707109200
            ],
            [
                153.58,
                1707195600
            ],
            [
                147.76,
                1707282000
            ],
            [
                142.88,
                1707368400
            ],
            [
                146.98,
                1707454800
            ],
            [
                146.57,
                1707714000
            ],
            [
                141.8,
                1707800400
            ],
            [
                145.87,
                1707886800
            ],
            [
                146.07,
                1707973200
            ],
            [
                148.23,
                1708059600
            ],
            [
                148.05,
                1708405200
            ],
            [
                150.8,
                1708491600
            ],
            [
                153.78,
                1708578000
            ],
            [
                155.1,
                1708664400
            ],
            [
                160.26,
                1708923600
            ],
            [
                179.69,
                1709010000
            ],
            [
                178.48,
                1709096400
            ],
            [
                165.65,
                1709182800
            ],
            [
                165.02,
                1709269200
            ],
            [
                167.86,
                1709528400
            ],
            [
                160.42,
                1709614800
            ],
            [
                159.52,
                1709701200
            ],
            [
                162.25,
                1709787600
            ],
            [
                158.52,
                1709874000
            ],
            [
                164.53,
                1710129600
            ],
            [
                163.75,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7717,
        "drug_name": "TRUDHESA (Dihydroergotamine)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-09-03",
        "link": "https:\/\/investors.impelnp.com\/news-releases\/news-release-details\/impel-neuropharma-announces-us-fda-approval-trudhesatm",
        "note": "Approved September 3, 2021.",
        "company_entity_id": 928,
        "company_ticker": "IMPL",
        "company_name": "Impel Pharmaceuticals Inc.",
        "company_price": "0.0400",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 23900031,
        "statuses": []
    }
]